Compare CCC & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCC | BEAM |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2020 | 2019 |
| Metric | CCC | BEAM |
|---|---|---|
| Price | $6.64 | $23.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $8.94 | ★ $50.75 |
| AVG Volume (30 Days) | ★ 9.2M | 1.8M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $1,057,001,000.00 | $24,000.00 |
| Revenue This Year | $10.22 | N/A |
| Revenue Next Year | $8.58 | $33.77 |
| P/E Ratio | $114.83 | ★ N/A |
| Revenue Growth | 11.88 | ★ 33.33 |
| 52 Week Low | $4.08 | $20.23 |
| 52 Week High | $8.68 | $38.26 |
| Indicator | CCC | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 34.38 |
| Support Level | $6.63 | $23.80 |
| Resistance Level | $7.79 | $28.96 |
| Average True Range (ATR) | 0.32 | 1.43 |
| MACD | -0.13 | -0.61 |
| Stochastic Oscillator | 32.34 | 2.26 |
CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies, and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, AI-enabled digital workflows. It operates in a single segment being Domestic segment, which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in the United States and China. The majority of the revenue is generated from the United States.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.